Drug Profile
MP 0250
Alternative Names: MP0250Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Molecular Partners AG
- Class Antineoplastics; Proteins; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Multiple myeloma
- Phase I/II Non-small cell lung cancer; Solid tumours
Most Recent Events
- 21 Jul 2022 MP 0250 is available for licensing as of 21 Jul 2022. https://www.molecularpartners.com/legacy-product-candidates/
- 21 Jul 2022 No development reported - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Austria (IV)
- 21 Jul 2022 No development reported - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Czech Republic (IV)